This company seems to have been delisted
Reason: Merged with Sun Pharma
Last recorded trade on: August 23, 2024
Source: https://www.prnewswire.com/news-releases/sun-pharma-completes-taro-merger-302180230.html
Reason: Merged with Sun Pharma
Last recorded trade on: August 23, 2024
Source: https://www.prnewswire.com/news-releases/sun-pharma-completes-taro-merger-302180230.html
Taro Pharmaceutical
TARO
₹3,723
Share price
0.00%
Change (1 day)
11.93%
Change (1 year)
Categories
Revenue for Taro Pharmaceutical (TARO)
Revenue in 2023 (TTM): ₹50.49 Billion
According to Taro Pharmaceutical's latest financial reports the company's current revenue (TTM 
) is ₹52.92 Billion. an increase over the revenue in the year 2022 that were of ₹47.13 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Taro Pharmaceutical from 1996 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 | ₹50.85 B | 7.88% |
| 2022 | ₹47.13 B | 11.8% |
| 2021 | ₹42.16 B | 0.16% |
| 2020 | ₹42.09 B | -9.15% |
| 2019 | ₹46.33 B | -0.38% |
| 2018 | ₹46.51 B | 6.64% |
| 2017 | ₹43.61 B | -32.3% |
| 2016 | ₹64.42 B | 4.26% |
| 2015 | ₹61.79 B | 20.98% |
| 2014 | ₹51.07 B | 12.15% |
| 2013 | ₹45.54 B | 27.79% |
| 2012 | ₹35.64 B | 33.24% |
| 2011 | ₹26.74 B | 52.31% |
| 2010 | ₹17.56 B | 5.83% |
| 2009 | ₹16.59 B | |
| 2005 | ₹13.59 B | 10.48% |
| 2004 | ₹12.30 B | -14.33% |
| 2003 | ₹14.36 B | 41.56% |
| 2002 | ₹10.14 B | 40.06% |
| 2001 | ₹7.24 B | 49.54% |
| 2000 | ₹4.84 B | 33% |
| 1999 | ₹3.64 B | 28.43% |
| 1998 | ₹2.83 B | 18.11% |
| 1997 | ₹2.40 B | 18.22% |
| 1996 | ₹2.03 B |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | ₹5.412 T | 10,125.96% | 🇺🇸 USA |
 Merck MRK | ₹5.538 T | 10,364.81% | 🇺🇸 USA |
 Johnson & Johnson JNJ | ₹7.740 T | 14,524.58% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | ₹1.439 T | 2,620.08% | 🇮🇱 Israel |
 GlaxoSmithKline GSK | ₹3.516 T | 6,544.52% | 🇬🇧 UK |
 Novartis NVS | ₹4.611 T | 8,613.09% | 🇨🇭 Switzerland |